SOLNA, STOCKHOLM REGION, SWEDEN – October 7, 2025 – Barnik Invest is proud to announce the official incorporation of its portfolio company, Bonipharmex AB. The establishment of the company is the result of a successful joint venture between StartUpPharma Sweden and DynalisPharma Switzerland, aimed at developing and commercializing a novel concept of holistic food supplements.
The transition to a standalone company marks a key milestone in the mission to deliver science-based dietary supplements tailored for different stages of life. As a Barnik Invest portfolio company, Bonipharmex AB combines the specialized strengths of its founding partners to create a unique offering in the global health and wellness market.
Bonipharmex AB will continue to focus on expanding its portfolio of holistic solutions, ensuring that every product meets the rigorous scientific standards expected by modern consumers.
For more information, please contact;
Hamid Bakhshi, CEO
Telephone: +46738531165
E-mail: info@barnikinvest.com
About Barnik Invest Group
Barnik Invest Group is a leading 360 solution partner for Life Science companies in the Nordics. The company provides a comprehensive suite of services to support its portfolio companies, including capital, clinical development, expertise, and commercialization. Through its fully owned subsidiaries, Medicorent and StartUpPharma, Barnik Invest offers CRO services, outsourcing, recruitment, distribution, product development, and commercialization solutions. Barnik’s mission is to nurture promising life science companies from early clinical development to commercialization, enabling them to achieve positive cash flows or successful exits, and ultimately enhancing patient well-being and improving human health worldwide. For more information, visit www.barnikinvest.com.
